EUVIMEDEUVIMED entdecken
Crossref

Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab

Rachel Porth, Tina Deyhim, Samantha Zullow, Loren G Rabinowitz, Laurie B Grossberg, Xavier Roblin, Stephane Paul iD, Adam S Cheifetz, Konstantinos Papamichael iD

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izae140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Rachel Porth und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachus…. Hauptthemen laut MEDLINE: Drug Monitoring, Antibodies, Monoclonal, Humanized, Gastrointestinal Agents, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are limited data regarding therapeutic drug monitoring (TDM) of non-anti-tumor necrosis factor therapy in inflammatory bowel disease (IBD). This study aimed to evaluate the efficacy of proactive TDM in IBD patients treated with intravenous (iv) vedolizumab (VDZ).

Methods

This single-center retrospective cohort study included consecutive IBD patients treated with maintenance iv VDZ therapy undergoing TDM from November 2016 to March 2023. Patients were followed through June 2023 and were divided in to 2 groups: those who had at least 1 proactive TDM vs those who underwent only reactive TDM. A survival analysis was performed to evaluate drug persistence, defined as no need for drug discontinuation due to loss of response, serious adverse event, or an IBD-related surgery.

Results

The study population consisted of 94 patients (proactive TDM, n = 72) with IBD (ulcerative colitis, n = 53). Patients undergoing at least 1 proactive TDM compared with patients having only reactive TDM demonstrated a higher cumulative probability of drug persistence (Log-rank P < .001). In multivariable Cox proportional hazard regression analysis, at least 1 proactive TDM was the only factor associated with drug persistence (hazard ratio, 14.3; 95% confidence interval [CI], 3.8-50; P < .001). A ROC analysis identified a VDZ concentration of 12.5 µg/mL as the optimal drug concentration threshold associated with drug persistence (area under the ROC curve: 0.691; 95% CI, 0.517-0.865; P = .049).

Conclusion

In this single-center retrospective study reflecting real-life clinical practice, proactive TDM was associated with increased drug persistence in patients with IBD treated with iv VDZ.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug MonitoringAntibodies, Monoclonal, HumanizedGastrointestinal AgentsInflammatory Bowel DiseasesHumansFemaleRetrospective StudiesMaleAdultMiddle AgedAdministration, IntravenousFollow-Up Studies

Stichwörter der Autor:innen

Crohn’s diseaseproactive therapeutic drug monitoringreactive therapeutic drug monitoringulcerative colitisvedolizumab

Substanzen

vedolizumabAntibodies, Monoclonal, HumanizedGastrointestinal Agents

Autor:innen und Institutionen

  • Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Gastroenterology, University Hospital of Saint-Etienne, Saint-Etienne, France.
  • Immunology laboratory, CIC1408, University Hospital of Saint-Etienne, Saint-Etienne, France.
  • CIRI (Centre International de Recherche en Infectiologie), Université Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon, Université Jean Monnet de Saint-Etienne, 10 Rue Tréfilerie, 42100 Saint-Etienne, France.

ORCID-Profile: Stephane Paul, Konstantinos Papamichael

Zitieren

APA

Porth, R., Deyhim, T., Zullow, S., Rabinowitz, L. G., Grossberg, L. B., Roblin, X., Paul, S., Cheifetz, A. S., & Papamichael, K. (2025). Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae140

Vancouver

Porth R, Deyhim T, Zullow S, Rabinowitz LG, Grossberg LB, Roblin X, et al. Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae140

BibTeX
@article{Porth2025,
  author = {Porth, Rachel and Deyhim, Tina and Zullow, Samantha and Rabinowitz, Loren G and Grossberg, Laurie B and Roblin, Xavier and Paul, Stephane and Cheifetz, Adam S and Papamichael, Konstantinos},
  title = {Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izae140}
}
Kostenlos starten →